BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 24948121)

  • 1. Anticancer drugs: Hitting SYK in B-ALL leukaemia.
    Harrison C
    Nat Rev Drug Discov; 2014 Jul; 13(7):494. PubMed ID: 24948121
    [No Abstract]   [Full Text] [Related]  

  • 2. Therapeutic potential of spleen tyrosine kinase inhibition for treating high-risk precursor B cell acute lymphoblastic leukemia.
    Perova T; Grandal I; Nutter LM; Papp E; Matei IR; Beyene J; Kowalski PE; Hitzler JK; Minden MD; Guidos CJ; Danska JS
    Sci Transl Med; 2014 May; 6(236):236ra62. PubMed ID: 24828076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polo-like-kinase 1 (PLK1) as a molecular target to overcome SYK-mediated resistance of B-lineage acute lymphoblastic leukaemia cells to oxidative stress.
    Uckun FM; Ozer Z; Qazi S; Tuel-Ahlgren L; Mao C
    Br J Haematol; 2010 Mar; 148(5):714-25. PubMed ID: 19912216
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting SYK kinase-dependent anti-apoptotic resistance pathway in B-lineage acute lymphoblastic leukaemia (ALL) cells with a potent SYK inhibitory pentapeptide mimic.
    Uckun FM; Ek RO; Jan ST; Chen CL; Qazi S
    Br J Haematol; 2010 May; 149(4):508-17. PubMed ID: 20151979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Getting Syk: spleen tyrosine kinase as a therapeutic target.
    Geahlen RL
    Trends Pharmacol Sci; 2014 Aug; 35(8):414-22. PubMed ID: 24975478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Specific inhibition of spleen tyrosine kinase suppresses leukocyte immune function and inflammation in animal models of rheumatoid arthritis.
    Coffey G; DeGuzman F; Inagaki M; Pak Y; Delaney SM; Ives D; Betz A; Jia ZJ; Pandey A; Baker D; Hollenbach SJ; Phillips DR; Sinha U
    J Pharmacol Exp Ther; 2012 Feb; 340(2):350-9. PubMed ID: 22040680
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibitors of switch kinase 'spleen tyrosine kinase' in inflammation and immune-mediated disorders: a review.
    Kaur M; Singh M; Silakari O
    Eur J Med Chem; 2013 Sep; 67():434-46. PubMed ID: 23917087
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Spleen tyrosine kinase inhibitors: a review of the patent literature 2010 - 2013.
    Norman P
    Expert Opin Ther Pat; 2014 May; 24(5):573-95. PubMed ID: 24555683
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spleen tyrosine kinases: biology, therapeutic targets and drugs.
    Riccaboni M; Bianchi I; Petrillo P
    Drug Discov Today; 2010 Jul; 15(13-14):517-30. PubMed ID: 20553955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spleen tyrosine kinase as a molecular target for treatment of leukemias and lymphomas.
    Uckun FM; Qazi S
    Expert Rev Anticancer Ther; 2010 Sep; 10(9):1407-18. PubMed ID: 20836676
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structural insights for design of potent spleen tyrosine kinase inhibitors from crystallographic analysis of three inhibitor complexes.
    Villaseñor AG; Kondru R; Ho H; Wang S; Papp E; Shaw D; Barnett JW; Browner MF; Kuglstatter A
    Chem Biol Drug Des; 2009 Apr; 73(4):466-70. PubMed ID: 19220318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comment on "Therapeutic targeting of Syk in autoimmune diabetes".
    Kapoor S
    J Immunol; 2011 Feb; 186(4):1885; author reply 1886-5. PubMed ID: 21289311
    [No Abstract]   [Full Text] [Related]  

  • 13. Identification of type-II inhibitors using kinase structures.
    Lovering F; McDonald J; Whitlock GA; Glossop PA; Phillips C; Bent A; Sabnis Y; Ryan M; Fitz L; Lee J; Chang JS; Han S; Kurumbail R; Thorarensen A
    Chem Biol Drug Des; 2012 Nov; 80(5):657-64. PubMed ID: 22759374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Spleen tyrosine kinase (Syk) is a potent target for GvHD prevention at different cellular levels.
    Leonhardt F; Zirlik K; Buchner M; Prinz G; Hechinger AK; Gerlach UV; Fisch P; Schmitt-Gräff A; Reichardt W; Zeiser R
    Leukemia; 2012 Jul; 26(7):1617-29. PubMed ID: 22301676
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective inhibition of spleen tyrosine kinase (SYK) with a novel orally bioavailable small molecule inhibitor, RO9021, impinges on various innate and adaptive immune responses: implications for SYK inhibitors in autoimmune disease therapy.
    Liao C; Hsu J; Kim Y; Hu DQ; Xu D; Zhang J; Pashine A; Menke J; Whittard T; Romero N; Truitt T; Slade M; Lukacs C; Hermann J; Zhou M; Lucas M; Narula S; DeMartino J; Tan SL
    Arthritis Res Ther; 2013 Oct; 15(5):R146. PubMed ID: 24286216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Highly potent and selective pyrazolylpyrimidines as Syk kinase inhibitors.
    Choi JS; Hwang HJ; Kim SW; Lee BI; Lee J; Song HJ; Koh JS; Kim JH; Lee PH
    Bioorg Med Chem Lett; 2015 Oct; 25(20):4441-6. PubMed ID: 26384287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Syk kinase as a treatment target for therapy in autoimmune diseases.
    Kyttaris VC; Tsokos GC
    Clin Immunol; 2007 Sep; 124(3):235-7. PubMed ID: 17662659
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery and SAR of novel 4-thiazolyl-2-phenylaminopyrimidines as potent inhibitors of spleen tyrosine kinase (SYK).
    Farmer LJ; Bemis G; Britt SD; Cochran J; Connors M; Harrington EM; Hoock T; Markland W; Nanthakumar S; Taslimi P; Ter Haar E; Wang J; Zhaveri D; Salituro FG
    Bioorg Med Chem Lett; 2008 Dec; 18(23):6231-5. PubMed ID: 18938080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic prospect of Syk inhibitors.
    Ruzza P; Biondi B; Calderan A
    Expert Opin Ther Pat; 2009 Oct; 19(10):1361-76. PubMed ID: 19670961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deregulated Syk inhibits differentiation and induces growth factor-independent proliferation of pre-B cells.
    Wossning T; Herzog S; Köhler F; Meixlsperger S; Kulathu Y; Mittler G; Abe A; Fuchs U; Borkhardt A; Jumaa H
    J Exp Med; 2006 Dec; 203(13):2829-40. PubMed ID: 17130299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.